IPHA analyst estimates

Innate Pharma (IPHA) analyst ratings, the average price target and its range, and every firm's latest call.

IPHA analyst ratings and price targets

DateFirmCallTarget
Aug 12, 2026BTIGInnate Pharma price target raised to $9 from $8 at BTIG$9.00
Aug 11, 2026Leerink PartnersLeerink upgrades Innate Pharma to Outperform after lacutamab deal$4.00
Aug 10, 2026H.C. WainwrightInnate Pharma price target raised to $7 from $5 at H.C. Wainwright$7.00
Oct 29, 2025H.C. WainwrightInnate Pharma upgraded to Buy from Neutral at H.C. Wainwright$5.00
Sep 17, 2025Leerink PartnersInnate Pharma downgraded to Market Perform from Outperform at Leerink$2.00